1、 靶向蛋白动态构象变化的药物发现
2、 肿瘤免疫系统的靶向调控

1、 国家自然科学基金面上项目, 82473848, 感染性和炎症性疾病治疗新策略：基于Zα结构域ZBP1抑制剂的发现、设计及调控细胞程序性坏死研究、 2025.01-2028.12、49 万元、在研、主持
2、 江苏省自然科学基金，优秀青年基金，基于蛋白动态构象变化的药物分子设计与发现，2024-09 至 2027-08，50万元，在研，主持
3、 国家自然科学基金面上项目，82273786、基于干扰蛋白多聚策略发现、设计新型STING抑制剂及其在自身免疫炎症性疾病中的应用探索、2023.01-2026.12、52 万元、在研、主持。
4、 国家自然科学基金面上项目, 82073766、基于STING的“开放-闭合”动态激活构象发现、设计新型STING激动剂及其在 肿瘤免疫治疗中的应用探索、 2021.01-2024.12、56万元、在研、主持。
5、 国家自然科学基金面上项目，81872737，基于诱导Phe199位移变化策略选择性抑制热休克蛋白内质网亚型Grp94蛋白的药物发现及其应用探索， 2019-01 至 2022-12，56万元，在研，主持

[1]. Nan-Nan Chen, Han Zhang, Qiang-Sheng Zhu, Ting Zeng, Wei Dai, Ye-Ling Zhou, Guo-Feng Xin, Bei-Duo Wu, Si-Jia Gong, Zheng-Yu Jiang*, Qi-Dong You*, and Xiao-Li Xu*. Development of Orally Bioavailable Amidobenzimidazole Analogues Targeting Stimulator of Interferon Gene (STING) Receptor. J. Med. Chem. 2023, 66, 8, 5584–5610
[2]. Hui Li, Sheng-Lie Zhang, Yan-Han Jia, Qian Li, Zi-Wen Feng, Shi-Duo Zhang, Wei Zheng, Ye-Ling Zhou, Lin-Lin Li, Xue-Chun Liu, Ya-Qiong Chen, Hui Peng*, Qi-Dong You*, and Xiao-Li Xu* Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. J. Med. Chem. 2023, 66, 2804−2831.
[3]. Qiangsheng Zhu, Nannan Chen, Xinjian Tian, Yeling Zhou, QiDong You*, and Xiaoli Xu* Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. J. Med. Chem. 2022, 65, 12, 8065–8090.
[4]. Li Li, Nannan Chen, Dandan Xia, Shicheng Xu, Wei Dai, Yuanyuan Tong, Lei Wang, Zhengyu Jiang*, Qidong You*, Xiaoli Xu*.  Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chemical Biology. 2021.28（10), 1446-1459.e6.
[5]. Shicheng Xu, Anping Guo, Nan-nan Chen, Wei Dai, Huan-aoyu Yang, Wenqin Xie, Mengjie Wang, Qi-Dong You*, Xiao-Li Xu*. Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects. Eur. J. Med. Chem. 2021.223, 113604.
[6] LeiWang, JingshengJiang, LixiaoZhang, QiuyueZhang, JianruiZhou,Li Li, Xiao-li Xu,* Qidong You*.Discovery and Optimization of Small Molecules Targeting theProtein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer J. Med. Chem. 2020 63 (3), 1281-1297.
[7]. Han Zhang，Qi-Dong You*，Xiao-Li Xu* Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective J. Med. Chem.2020, 63 (8):3785-3816
[8]. Li Li, Lei Wang, Qi-Dong You,* and Xiao-Li Xu* Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. J. Med. Chem. 2020, 63, 5, 1798-1822. IF: 6.023.
[9]. Fen Jiang, An-ping Guo, Jia-chen Xu, Qi-Dong You,*Xiao-Li Xu* Discovery of a Potent Grp94 Selective Inhibitor with Anti- Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis. J. Med. Chem. 2018, 61, 9513−9533.
[10]. Fen Jiang, Hui-Jie Wang, Yu-Hui Jin, Qiong Zhang, Zhi-Hui Wang, Jian-Min Jia,Fang Liu, Lei Wang,Qi-Chao Bao, Dong-Dong Li, Qi-Dong You,*and Xiao-Li Xu*.Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90. J. Med. Chem. 2016, 59, 10498-10519.
[11]. Wang, L.1; Xu, X.1; Jiang, Z.*; You, Q.*, Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery. 2020. Acta Pharm Sin B. 2020. 10(10):1904-1925.